Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989819 | 0.96 | FTO (0.52) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL6738373 | 0.96 | FTO (0.52) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL2314510 | 0.89 | FTO (0.60) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL16116120 | 0.89 | FTO (0.54) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL4824384 | 0.89 | FTO (0.54) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL19206099 | 0.88 | FTO (0.50) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL9192235 | 0.86 | FTO (0.49) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL7647553 | 0.86 | FTO (0.56) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL4825622 | 0.86 | FTO (0.56) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL2186619 | 0.86 | CYP3A4 (0.40) | FTOMAPTHPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MOLECULAR PROBES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | LIFE TECHNOLOGIES CORP (US) | 2016-05-19 | — | — | US | disclosed |
| US-8865891-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130090470-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | Life Technologies Corporation (US) | 2013-04-11 | — | — | US | disclosed |
| US-8318450-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120040380-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | Life Technologies Corporation (US) | 2012-02-16 | — | — | US | disclosed |
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | INVITROGEN CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1711504-A2 | DERIVATIVES OF CEPHALOSPORIN AND CLAVULANIC ACID FOR DETECTING BETA-LACTAMASE IN A SAMPLE | Molecular Probes Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005071096-A9 | DERIVATIVES OF CEPHALOSPORIN AND CLAVULANIC ACID FOR DETECTING BETA-LACAMASE IN A SAMPLE | — | 2006-02-02 | — | — | WO | disclosed |
| US-20050227309-A1 | Optically-detectable enzyme substrates and their method of use | MOLECULAR PROBES, INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2005071096-A2 | DERIVATIVES OF CEPHALOSPORIN AND CLAVULANIC ACID FOR DETECTING BETA-LACAMASE IN A SAMPLE | MOLECULAR PROBES, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | FTO 460/4885MAPT 2586/4885HPGD 650/4885 |
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | FTO 460/4885MAPT 2586/4885HPGD 650/4885 |
| US-20130090470-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | MGAM, LCT, GAA | FTO 460/4885MAPT 2586/4885HPGD 650/4885 |
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | MGAM, LCT, GAA | FTO 460/4885MAPT 2586/4885HPGD 650/4885 |
| US-20050227309-A1 | Optically-detectable enzyme substrates and their method of use | MGAM, LCT, GAA | FTO 460/4885MAPT 2586/4885HPGD 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.